Development and Validation of Oseltamivir Carboxylate by Suchada Jongrungruangchok, Suchada Jongrungruangchok et al.
ไทยเภสชัศาสตรและวิทยาการสุขภาพ ป 6 ฉบับ 1, มค. – มีค. 2554 12  Thai Pharm Health Sci J Vol. 6 No. 1, Jan. – Mar. 2011 
 
Development and Validation of Oseltamivir Carboxylate  
and Oseltamivir Phosphate Quantification in Human Plasma by HPLC 
  
 
นิพนธตนฉบบั  Original Article
 
 
สุชาดา จงรุงเรืองโชค1, บุญฑริกา บุญญาภิวัฒน2 และ ธนภัทร  
ทรงศักด์ิ1* 
Suchada Jongrungruangchok1, Boontarika Boonyapiwat2 and Thanapat 
Songsak1* 
 
1 ภาควิชาเภสัชเวทและเภสัชเคมีวิเคราะห คณะเภสัชศาสตร มหาวิทยาลัยรังสิต จ. ปทุมธานี 
12000  
2 สาํนักยาและวัตถุเสพติด กรมวิทยาศาสตรการแพทย กระทรวงสาธารณสขุ จ. นนทบุรี 11000 
  
1 Dept. of Pharmacognosy and Pharmaceutical Chemistry, Faculty of Pharmacy, 
Rangsit University, Pathum Thani, Thailand 12000  
2 Bureau of Drug and Narcotic, Department of Medical Sciences, Ministry of Public 
Health, Nonthaburi, Thailand 11000 
 
* ติดตอผูนิพนธ: author: tsongsak@yahoo.com * Corresponding author: tsongsak@yahoo.com  
 
วารสารไทยเภสัชศาสตรและวิทยาการสุขภาพ 2554;6(1):12-16 Thai Pharmaceutical and Health Science Journal 2011;6(1):12-16 
 
 
 
บทคัดยอ 
วัตถุประสงค: เพ่ือพัฒนาวิธีวิเคราะหหาปริมาณโอเซลทามิเวียร คารบอกซิเลต 
(OC) และโอเซลทามิเวียร ฟอสเฟต (OP) ในพลาสมาของมนุษย โดยใชวิธี HPLC 
อยางงาย วิธีการศึกษา: ในการแยกใชคอลัมนชนิด Hypersil BDS cyano 5 μm 
(ความยาว 250 mm เสนผานศูนยกลาง 4.6 mm) ตรวจวัดโดย UV ที่ 230 nm 
ระบบเฟสเคลื่อนที่ คือ ระบบการปรับอัตราสวน โดยเริ่มตนที่ 50 มิลลิโมล 
ammonium acetate : acetonitrile (95:5) นาน 4 นาที และปรับความเขมขนเปน 
50 มิลลิโมล ammonium acetate: acetonitrile (70:30) 7 นาที ที่ 4 นาทีสุดทาย
ปรับเปน 50 มิลลิโมล ammonium acetate: acetonitrile (95:5) ผลการศึกษา: 
ไดคาสัมประสิทธิ์การตัดสินใจของ OC และ OP เทากับ 0.9994 และ 0.9991 
ตามลําดับ โดย OC และ OP แยกออกมาที่เวลา 4.35 และ 11.04 นาที ตามลําดับ 
คาปริมาณต่ําสุดที่สามารถวิเคราะหไดอยางถูกตอง (LOQ) เทากับ 1.5 μg/ml คา
สัมประสิทธิ์ความแปรปรวนในระหวางวันและภายในวันของ OC อยูในชวง 2.15  
- 7.19% และ 1.97 - 6.63% ตามลําดับ สวนของ OP พบในชวง 2.41 - 8.52% 
และ 1.90 - 8.57% ตามลําดับ สรุป: ผลวิเคราะหหาปริมาณโอเซลทามิเวียร คาร
บอกซิเลต และโอเซลทามิเวียร ฟอสเฟต ในพลาสมาของมนุษย โดยใชวิธี HPLC 
ทําไดงายและรวดเร็ว  
คําสําคัญ: โอเซลทามิเวียร คารบอกซิเลต, โอเซลทามิเวียร ฟอสเฟต, HPLC, 
การตรวจสอบความถูกตองของวิธีวิเคราะห 
 
Abstract 
Objective: To develop a simple HPLC analysis for the quantification of 
oseltamivir carboxylate (OC) and oseltamivir phosphate (OP) in human 
plasma. Method: Chromatographic separation was carried out using 
Hypersil BDS cyano 5 μm column (length 250 mm, inner diameter 4.6 mm) 
with UV detection at 230 nm. The gradient system composed of 50 mM 
ammonium acetate: acetonitrile (95:5) for 4 min, followed by 50 mM 
ammonium acetate: acetonitrile (70:30) for 7 min, and finally 50 mM 
ammonium acetate: acetonitrile (95:5) for 4 min. Results: Coefficients of 
determination for the quantification of OC and OP were 0.9994 and 0.9991, 
respectively, with retention times of 4.35 and 11.04 min, respectively. The 
method limit of quantification for both compounds was 1.5 μg/ml. 
Coefficients of variation for the between- and within-day precision of OC 
were 2.15 - 7.19% and 1.97 - 6.63%, respectively, and those of OP were 
2.41 - 8.52% and 1.90 - 8.57%, respectively. Conclusion: A simple and 
reliable HPLC quantification method of oseltamivir carboxylate and 
oseltamivir phosphate in human plasma was successfully validated.  
Keywords: oseltamivir carboxylate, oseltamivir phosphate, HPLC, method 
validation  
 
Introduction
Oseltamivir phosphate (OP) is an antiviral drug used for 
the treatment and prophylaxis of influenza virus A and 
influenza virus B.1 OP is an ethyl ester pro-drug which is 
rapidly and extensively metabolized by esterases in the 
gastrointestinal tract and liver to its active form, oseltamivir 
carboxylate (OC) (Figure 1).2,3  
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Figure 1 Oseltamivir phosphate, an ethyl ester pro-drug, rapidly 
and extensively metabolized by esterases in the 
gastrointestinal tract and liver to its active form, 
oseltamivir carboxylate.  
Various analytical techniques have been explored to 
analyze OP and OC in the biological fluids and 
pharmaceutical preparations.1,3-13 Green and co-workers 
reported the colorimetric method to approximate the amount 
of OP in capsules.7 The HPLC-fluorescent detection was 
used to quantify OC in rat plasma by derivatizing OC with 
naphthalenedialdehyde; however, the method itself was toxic 
due to potassium cyanide (KCN) and required long 
incubation period for derivatization.8 An enzymatic assay 
based on neuraminidase inhibition was also reported for the 
analysis of OC.9 The HPLC methods with UV detection have 
been employed for the analysis of OC but not OP in human 
serum.10,11 To date, there is no quantification method of both 
OC and OP in human serum by HPLC analysis.  
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Among the methods studied for the determination of OC 
and OP in various matrices to date, liquid chromatography is 
most commonly used. The LC-MS/MS method with solid 
phase extraction (SPE) was used to analyze rat and mouse 
brain samples with lower limit of quantification (LLOQ) of 60 
ng/g for OP and OC.3 Lindegårdh and coworkers also 
reported the LLOQ of 5 and 30 ng/ml for OP and OC, 
respectively, in urine by using respectively.12 The present 
work reports the validation of a simple HPLC method for the 
quantification of both OP and its metabolite, OC, in human 
plasma.  
 
Materials and Methods 
Materials and reagents  
OP was a generous gift from the Government Pharma-
ceutical Organization, Thailand. HPLC grade acetonitrile 
(J.T. Baker, USA) was used to prepare the mobile phase. 
Ultrapure water was obtained from a MilliQ Millipore system. 
Trichloroacetic acid and ammonium acetate were from Fluka, 
Buchs, Switzerland. Human plasma was kindly provided by 
the Thai Red Cross Society. 
 
Instruments  
The HPLC system was composed of a pump (model 
G13114) and autosampler connected with a Diode Array 
detector (model G1315A) (Agilent Technologies, Palo Alto, 
CA, USA). A class LC Chem Station G2170AA Data system 
(Agilent Spectral Module G2180AA) was used for data 
processing.   
 
Synthesis of oseltamivir carboxylate (OC)  
OP (0.41g, 1mmol) was dissolved in water (3 mL) and 
treated with triethylamine (1 mL). The mixture was stirred 
under nitrogen at room temperature overnight. The reaction 
mixture was then evaporated under reduced pressure and 
dried in high-vacuum oven overnight to obtain OC. The 
identity of OC was investigated by 1H and 13C nuclear 
magnetic resonance (NMR) and mass spectrometry. 
 
Chromatographic conditions  
Separation was accomplished using a BDS Hypersil 
Cyano column (length 250 mm, internal diameter 4.6 mm, 
particle size 5 μm), and with UV detection at 230 nm. The 
chromatographic separation was achieved using a gradient 
system (Table 1).  
 
Table1 Gradient system used in chromatographic separation. 
Time (min) Ratio (50 mM ammonium acetate : acetonitrile) 
0 – 4 95 : 5 
5 - 12 70 : 30 
13 - 17 95 : 5 
 
Standard and sample preparation  
Stock solutions of OC and OP at the concentration of 1 
mg/ml were prepared in ultrapure water. Standard OC and 
OP solutions (1.5 - 50 μg/ml) were obtained by serial 
dilutions using ultrapure water.  
The plasma was spiked with the OC and OP stock 
solutions to prepare the working samples at a concentration 
range of 1.5 - 50 μg/ml. Plasma (0.5 ml) was mixed with 
20% w/v trichloroacetic acid (0.1 ml), vortexed for 10 min 
and centrifuged at 6,000 rpm for 5 min. The supernatant was 
collected and analyzed by HPLC.  
   
Validation 
Validation was performed following the FDA guidelines 
for bioanalytical methods.14 The method was validated as 
regards its specificity, linearity, accuracy, precision (within- 
and between-day), sensitivity and stability. The stability of 
OC and OP samples was investigated after three consec-
utive freeze-thaw cycles.  
To determine the accuracy of the method, three standard 
solutions with low, intermediate and high concentrations (1.5, 
10, and 50 μg/ml, respectively) were analyzed. The percent-
tage recovery was performed by six determinations and 
calculated by the relationship between the experimental 
concentration (Cexp) and the theoretical concentration (Ctheo) 
expressed as percentage using the following equation: 100x 
(Cexp/ Ctheo).  
To evaluate the within- and between-day precision, six 
replicates of three standard solutions at low, medium and 
high concentrations were assayed on the same day and six 
consecutive days, respectively.  
  
Calibration  
Linearity was studied at a concentration range of 1.5 - 50 
μg/ml. The standard curve was analyzed by linear regression 
of peak height against OC and OP concentrations. Six 
concentrations of OC and OP standard solutions were 
carried out in six replicates on the same day. The correlation 
coefficient calibration and the regression analysis were 
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performed without applying any type of mathematical 
transformation or data weighing.  
  
Results and Discussions 
OC appeared as white foam with 1H NMR (360 MHz, 
D2O) δ 6.56 (t, J=2.1 Hz, 1H, C2-H), 4.34 (d, J=9.0 Hz, 1H, 
C3-H), 4.09 (dd, J=9.0, 11.7 Hz, 1H, C4-H), 3.63-3.56 (m, 2H, 
C5-H and 3-OCH(Et)2), 2.95 and 2.53 (ABX, J=5.5, 11.8, 
17.1 Hz, 2H, C6-H2), 2.15 (s, 3H, COCH3), 1.67-1.49 (m, 4H, 
2CH2CH3), 0.96 (t, J=7.4 Hz, 3H, CH2CH3), 0.91 (t, J=7.5 Hz, 
3H, CH2CH3). 
13C NMR (100 MHz, D2O) δ 175.56 (C), 
174.23 (C), 133.51 (C), 132.84 (CH), 84.58 (CH), 76.10 
(CH), 53.50 (CH), 50.04 (CH), 30.06 (CH2), 25.87 (CH2), 
25.54 (CH2), 22.73 (CH3), 8.93 (CH3), 8.85 (CH3). m/z 285 
(M+H)+. These results confirmed identity of the compound as 
OC.  
By using the developed sample preparation and 
validated chromatographic system, there were no inter-
ferences on the OC and OP peaks due to the components of 
the plasma samples. OC and OP were eluted at 4.35 and 
11.04 min, respectively (Figure 2).  
 
 
Figure 2 HPLC chromatogram showing the extract of plasma 
sample spiked with 50μg/ml OC and OP. Peak 
identifications at 4.35 and 11.04 min correspond to 
OC and OP respectively.  
 
The recovery of the extraction of OC from human plasma 
at the concentrations of 1.5, 10 and 50 μg/ml ranged from 
85.46 to 88.75%, and that of OP was from 87.23 to 90.67% 
(Table 2).  
 
Table 2 Recoveries of OC and OP of the extracts. 
Compound 
% Recovery 
1.5 μg/ml 10 μg/ml 50 μg/ml 
OC 85.46 86.71 88.75 
OP 87.23 87.25 90.67 
The limits of quantification (LOQ) for OC and OP of the 
method were 1.5 μg/ml. Coefficients of correlation of the OC 
and OP calibration curves were greater than 0.99 (Figures 3 
and 4). The results of the slope and ordinate values of the 
calibration curves were presented in Table 3.  
 
 
Figure 3 Linear relationship between peak heights and 
concentrations for the calibration range of OC (1.5 - 
50 μg/ml). 
 
 
Figure 4 Linear relationship between peak heights and 
concentrations for the calibration range of OP (1.5 - 
50 μg/ml).  
 
Table 3 Calibration curve parameters from linear regression 
analysis.  
Sample Concentration 
μg/ml Slope Intercept 
Coefficient of 
Determination (r2) 
OC 1.5-50  1.225 0.704 0.9994 
OP 1.5-50  1.332 0.558 0.9991 
 
The accuracy of the method was evaluated using three 
concentrations (low, intermediate and high) of the calibration 
at 1.5 - 50 μg/ml for OC and OP. Accuracy was measured 
using six determinations per concentration. The mean values 
were within 15% of the actual value except at LOQ, where it 
should not deviate by more than 20%.14 The % recoveries of 
OC and OP ranged from 86.85 to 92.87% and 85.99 to 
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89.28%, respectively (Table 4). The accuracy results 
demonstrated that the results of the mean tests were close 
to the true concentrations of the analytes.  
 
Table 4 Accuracy of OC and OP quantification.  
Sample 
Concentration 
(μg/ml) 
% Recovery*  
(Cexp/ Ctheo)x100 
S.D. 
    
OC 1.5 86.85 0.13 
 10 89.85 0.62 
 50 92.87 1.23 
 Mean ± CV 89.86 0.66 
    
OP 1.5 85.99 0.15 
 10 87.35 0.68 
 50 89.28 1.43 
 Mean ± CV 87.46 0.75 
*Based on six determinations for each concentration.  
 
The % coefficients of variation (CV) of the within-day 
precision for OC and OP were from 1.97 to 6.63% and 1.90 
to 8.57%, respectively. The values of CV of the between-day 
precision for the OC and OP were between 2.15 - 7.19% 
and 2.41 - 8.52%, respectively (Table 5).  
 
Table 5 Repeatability (within-day precision) and reproducibility 
(between-day precision) of the method.  
Sample Concentration (μg/ml) 
Mean response 
± S.D. C.V. (%) 
Within-day precision 
OC 1.5 1.81 ± 0.12 6.63 
 10 12.24 ± 0.29 2.37 
 50 57.90 ± 1.14 1.97 
OP 1.5 1.75 ± 0.15 8.57 
 10 12.88 ± 0.27 2.10 
 50 60.49 ± 1.15 1.90 
Between-day precision 
OC 1.5 1.78 ± 0.13 7.19 
 10 12.21 ± 0.62 5.08 
 50 57.16 ± 1.23 2.15 
OP 1.5 1.76 ± 0.15 8.52 
 10 12.56 ± 0.68 5.41 
 50 59.41 ± 1.43 2.41 
 
The effects of freeze-thaw cycle on the stability of OC 
and OP were evaluated at low, medium and high 
concentrations of the concentration range of 1.5 – 50 μg/ml. 
The tests were conducted at -20°C and -70°C as freezing 
temperature, and room temperature as thawing temperature. 
The sample recoveries were determined after three freeze-
thaw cycles. The recoveries of OC and OP storing at -20°C 
were in the range between 87.37 - 92.68% and 83.47 - 
87.16%, respectively (Table 6). On the other hand, those of 
OC and OP stored at -70 °C ranged between 82.98 - 
92.20% and 89.39 - 93.01%, respectively. The results of 
stability test demonstrated that OC and OP were stable and 
no degradation was found due to the freeze-thaw process. 
OC and OP were stable in plasma during the assay period. 
The recovery of the stability of OC and OP were in a range 
of 82.98 - 93.01%, close to the determination of OC and OP 
in ferret and rat plasma reported by Wiltshire and co-workers 
(80.2 - 102.7%).3 
 
Table 6 Freeze and thaw stability.   
Sample Concentration (μg/ml) 
% Recovery (Mean ± S.D.)  
(Third-cycle) 
-20 °C -70 °C 
OC 1.5 87.37 ± 0.18 82.98 ± 0.09 
 10 92.68 ± 0.54 88.58 ± 0.34 
 50 89.29 ± 1.43 92.20 ± 1.75 
OP 1.5 83.47 ± 0.24 90.68 ± 0.05 
 10 85.48 ± 0.49 89.39 ± 0.74 
 50 87.16 ± 1.18 93.01 ± 1.41 
 
The results proved that a simple HPLC method was 
successfully validated. The method was reliable for the 
quantification of OC and OP in human plasma. Because 
solid phase extraction, commonly used in various studies, is 
relatively expensive, the sample preparation by acid 
precipitation in this study benefits the reduction of analysis 
cost. As OC and OP are highly soluble in water, 
trichloroacetic acid is an appropriate choice for protein 
precipitation. The results also proved that no matrix effects 
were detected. The validated HPLC method used low 
amount of organic solvent; as a result, it had not only low 
direct environmental toxicity but also low risk to the health of 
analyst.  
The LOD of 0.95 μg/ml for OC and OP in this study was 
higher than the LLOQ of 1 ng/ml for OP and OC in human 
plasma and urine using LC-tandem MS13 and the LOQ of 
0.05 μg/ml for OC in rat plasma using fluorescent detection.8 
However, HPLC/fluorescence method by pre-column derivati-
zation with naphthalenedialdehyde was not available for a 
large number of plasma samples because the method 
required long incubation period and the use of KCN as the 
derivatizing agent can cause toxicity.8 It is commonly 
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accepted that LC-MS-MS facilitates the injection of low 
sample volume and MS-MS detection is more sensitive than 
UV and fluorescent detection; nevertheless, the cost of 
instrument hinders the implementation of the technique in 
some laboratories. The high LOQ values for the determina-
tion of OC and OP achieved in this study were due to the 
fact that the old generation of diode array detector was 
employed. It is commonly known that the diode array 
detector is less sensitive than the normal UV-VIS detector. 
Therefore, the use of UV-VIS detector will benefit lower LOQ 
values of both OC and OP. This study is a prototype of the 
use of a simple and reliable HPLC method for the 
determination of OC and OP in human plasma.  
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